Key result
Systemic administration of α-GalCer in CVB3-infected mice reduced viral titres, ameliorated heart damage, and improved the disease course compared with untreated mice.
Why the study?
Does α-galactosylceramide prevent lethal myocarditis in mice infected with Coxsackievirus B3?
Population
Mice with Coxsackievirus B3 (CVB3)-induced myocarditis
Comparison
Systemic administration of α-galactosylceramide vs Untreated CVB3-infected mice
Design
Preclinical
Authors
Loading...
α-GalCer may protect against CVB3 myocarditis in mice; leaves open translation to human viral disease.
Does α-galactosylceramide prevent lethal myocarditis in mice infected with Coxsackievirus B3?
Systemic administration of α-galactosylceramide protects against lethal Coxsackievirus B3-induced myocarditis in mice by modulating the early anti-viral immune response.
Wu et al. (2010) studied Coxsackievirus B3 (CVB3)-induced myocarditis. α-galactosylceramide (α-GalCer) vs. Untreated mice was evaluated on Viral transcription and titres, heart damage, and disease course. Systemic administration of α-GalCer in CVB3-infected mice reduced viral titres, ameliorated heart damage, and improved the disease course compared with untreated mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: